tetano
Editor, Senior Moderator
Exp Ther Med
. 2023 Oct 9;26(6):545.
doi: 10.3892/etm.2023.12244. eCollection 2023 Dec. Elevated matrix metalloproteinase‑9 expression is associated with COVID‑19 severity: A meta‑analysis
Ling Ding[SUP] 1 2 [/SUP], Haipeng Guo[SUP] 1 2 [/SUP], Chao Zhang[SUP] 1 2 [/SUP], Huixin Jin[SUP] 1 2 [/SUP], Xuyang Guo[SUP] 1 2 [/SUP], Tong Li[SUP] 1 2 [/SUP]
Affiliations
The present meta-analysis investigated the clinical value of serum matrix metalloproteinase (MMP)-9 levels in Coronavirus Disease 2019 (COVID-19) patients. Studies assessing the outcomes of patients with COVID-19 in correlation with the MMP-9 levels were retrieved from PubMed, Web of Science, EMBASE, Cochrane, WANFANG, and CNKI. A meta-analysis was performed to compare the serum MMP-9 levels between different patient groups: Severe vs. non-severe; acute respiratory distress syndrome (ARDS) vs. non-ARDS; non-survivors vs. survivors; neurologic syndrome vs. non-neurologic syndrome; and obese diabetic vs. non-obese diabetic. A total of 2,062 COVID-19-confirmed patients from 12 studies were included in this meta-analysis. The serum MMP-9 levels were significantly higher in patients with severe COVID-19 than in those with non-severe COVID-19 [weighted mean difference (WMD) 246.61 (95% confidence interval (CI), 115.86-377.36), P<0.001]. Patients with ARDS exhibited significantly higher MMP-9 levels than those without ARDS [WMD 248.55 (95% CI, 63.84-433.25), P<0.001]. The MMP-9 levels in the non-survivors did not significantly differ from those in the survivors [WMD 37.79 (95% CI, -18.08-93.65), P=0.185]. Patients with comorbidities, including neurological syndromes, and obese diabetic patients had significantly higher MMP-9 levels than those without comorbidities [WMD 170.73 (95% CI, 95.61-245.85), P<0.001]. Serum MMP-9 levels were associated with COVID-19 severity and may serve as a therapeutic target for improving the prognosis of patients with COVID-19.
Keywords: COVID-19; MMP-9; comorbidity; mortality; severity.
. 2023 Oct 9;26(6):545.
doi: 10.3892/etm.2023.12244. eCollection 2023 Dec. Elevated matrix metalloproteinase‑9 expression is associated with COVID‑19 severity: A meta‑analysis
Ling Ding[SUP] 1 2 [/SUP], Haipeng Guo[SUP] 1 2 [/SUP], Chao Zhang[SUP] 1 2 [/SUP], Huixin Jin[SUP] 1 2 [/SUP], Xuyang Guo[SUP] 1 2 [/SUP], Tong Li[SUP] 1 2 [/SUP]
Affiliations
- PMID: 37928509
- PMCID: PMC10623216
- DOI: 10.3892/etm.2023.12244
The present meta-analysis investigated the clinical value of serum matrix metalloproteinase (MMP)-9 levels in Coronavirus Disease 2019 (COVID-19) patients. Studies assessing the outcomes of patients with COVID-19 in correlation with the MMP-9 levels were retrieved from PubMed, Web of Science, EMBASE, Cochrane, WANFANG, and CNKI. A meta-analysis was performed to compare the serum MMP-9 levels between different patient groups: Severe vs. non-severe; acute respiratory distress syndrome (ARDS) vs. non-ARDS; non-survivors vs. survivors; neurologic syndrome vs. non-neurologic syndrome; and obese diabetic vs. non-obese diabetic. A total of 2,062 COVID-19-confirmed patients from 12 studies were included in this meta-analysis. The serum MMP-9 levels were significantly higher in patients with severe COVID-19 than in those with non-severe COVID-19 [weighted mean difference (WMD) 246.61 (95% confidence interval (CI), 115.86-377.36), P<0.001]. Patients with ARDS exhibited significantly higher MMP-9 levels than those without ARDS [WMD 248.55 (95% CI, 63.84-433.25), P<0.001]. The MMP-9 levels in the non-survivors did not significantly differ from those in the survivors [WMD 37.79 (95% CI, -18.08-93.65), P=0.185]. Patients with comorbidities, including neurological syndromes, and obese diabetic patients had significantly higher MMP-9 levels than those without comorbidities [WMD 170.73 (95% CI, 95.61-245.85), P<0.001]. Serum MMP-9 levels were associated with COVID-19 severity and may serve as a therapeutic target for improving the prognosis of patients with COVID-19.
Keywords: COVID-19; MMP-9; comorbidity; mortality; severity.